Pulmonary Cell News 6.48 December 7, 2017 | |
| |
TOP STORYEpigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer Using in vitro-treated non-small-cell lung cancer cell lines, scientists elucidated an interferon α/β-based transcriptional program with accompanying upregulation of antigen presentation machinery, mediated in part through double-stranded RNA induction. This was accompanied by suppression of MYC signaling and an increase in the T cell chemoattractant CCL5. [Cell] Abstract | Press Release | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Thyroid Hormone Inhibits Lung Fibrosis in Mice by Improving Epithelial Mitochondrial Function After bleomycin-induced injury, thyroid hormone promoted mitochondrial biogenesis, improved mitochondrial bioenergetics and attenuated mitochondria-regulated apoptosis in alveolar epithelial cells both in vivo and in vitro. [Nat Med] Abstract | Press Release Investigators present an interrupted reprogramming strategy to generate induced progenitor-like cells using carefully timed expression of induced pluripotent stem cell reprogramming factors from non-proliferative club cells. [Stem Cell Reports] Full Article | Press Release Researchers investigated if different allergens induce metabolite damage-associated molecular patterns (DAMPs) such as ATP and uric acid release in human bronchial epithelial cells. [Clin Exp Allergy] Abstract The authors demonstrated that miR-200b/c was downregulated, whereas ZEB1/2 was upregulated in the development of lipopolysaccharide-induced early pulmonary fibrosis. miR-200b/c exerted a protective effect by targeting ZEB1/2, which may be associated with the inhibition of p38 MAPK and transforming growth factor-β (TGF-β)/smad3 signaling pathways. [Lab Invest] Abstract LUNG CANCERResearchers describe caveolin-1 (Cav1) as an anti-metastatic regulator in mouse models of lung and breast cancer pulmonary metastasis. Using clodronate depletion of macrophages, they demonstrated that macrophage Cav1 signaling is critical for metastasis and not for primary tumor growth. [Cell Rep] Full Article | Press Release | Graphical Abstract Scientists found that the inhibition of proliferation potential by cisplatin was reduced in cobalt chloride-induced hypoxia in lung cancer cells. Hypoxia caused alterations in epithelial–mesenchymal transition (EMT), which were detected by cellular morphology and EMT protein markers, and in stemness analyzed by spheroid formation and marker molecules [Cancer Lett] Abstract Researchers investigated the role of miR-106b-5p in non-small cell lung cancer (NSCLC). They found a relatively higher miR-106b-5p and lower BTG3 expression in NSCLC specimens and cell lines. [Cell Physiol Biochem] Full Article Silencing of the ELF3 gene in non-small cell lung cancer (NSCLC) cells inhibited the proliferation and metastasis significantly in vitro and in vivo. Conversely, overexpression of ELF3 in NSCLC cells promoted cancer growth and metastasis in vitro. [Int J Biochem Cell Biol] Full Article Investigators explored the relationship of cathepsin L, micRNA-200c and drug resistance, and the potential regulatory mechanisms in human lung cancer A549 cells and A549/TAX cells in vitro. [Acta Pharmacol Sin] Abstract | |
| |
REVIEWSThe authors give an overview of the role that chemoattractants and cytokines play in these neutrophil-dominated lung pathologies. The most frequently applied treatments in CF and primary ciliary dyskinesia and new experimental therapies to reduce neutrophil-dominated airway inflammation are described. [Cell Mol Immunol] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSVertex Pharmaceuticals Inc. announced positive results from an open-label Phase III study of KALYDECO® in children with cystic fibrosis ages one to two years who have one of ten mutations in the cystic fibrosis transmembrane conductance regulator gene. [Vertex Pharmaceuticals Inc.] Press Release Genentech announced results from the positive, pivotal Phase III IMpower150 study of TECENTRIQ® and Avastin® plus chemotherapy in people with previously untreated, advanced non-squamous non-small cell lung cancer. [Genentech Inc.] Press Release TRACON Doses First Patient in Phase Ib Study of TRC105 with Opdivo® in Patients with Lung Cancer TRACON Pharmaceuticals announced that the first patient has been dosed in its Phase Ib clinical trial of TRC105 in combination with Opdivo® in patients with non-small cell lung cancer. [TRACON Pharmaceuticals, Inc.] Press Release | |
| |
POLICY NEWSUS Graduate Students in Uproar over Proposed Tax Hike Many US universities waive tuition for students who conduct research or teach. But a provision in a tax bill passed by the US House of Representatives would add that tuition to students’ taxable income. [Nature News] Editorial Hundreds of German Universities Set to Lose Access to Elsevier Journals Around 200 German universities will lose their subscriptions to Elsevier journals within weeks, because negotiations have failed to end a long-term contract dispute. [Nature News] Editorial
| |
EVENTSNEW 11th Dutch Stem Cell Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Human Airway Stem Cell Biology (Cornell University) PhD Studentship – Heterogeneity in Small Cell Lung Cancer (CRUK Manchester Institute) Postdoctoral Fellow/Associate – Inflammation and Fibrosis (Rhode Island Hospital) Postdoctoral Position – Lung Cancer (Helmholtz Centre for Environmental Research) Postdoctoral Fellow – Disease Mechanism (University of California, San Diego) Postdoctoral Fellow – Lung Cancer (Moffitt Cancer Center) Postdoctoral Position – Immunology & Respiratory Diseases (Boehringer Ingelheim) Faculty Position – Cancer Experimental Therapeutics (University of New Mexico) PhD Position – Pulmonary Research (Helmholtz Zentrum München) Postdoctoral Position – Immunology/Molecular Biology (Helmholtz Zentrum München) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|